Kingsoft Cloud Holdings Limited vs Relay Therapeutics Inc. Common Stock — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Relay Therapeutics Inc. Common Stock trades at $18.28 (market cap $3.82B). The key difference: Relay Therapeutics Inc. Common Stock is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| KC | RLAY | |
|---|---|---|
Market Cap | $2.71B | $3.82B |
Volume | 1,993,765 | 4,332,079 |
Sector | Technology | Health |
52-Week High | $18.21 | $20.75 |
52-Week Low | $8.58 | $6.03 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $3.03B | $2.93B |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.26, up 0.27% with bearish technical signals but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. While still reporting net losses, gross margins improved significantly and AI cloud services are emerging as a key growth driver, with billings surging 82% year-over-year.
KC presents a compelling turnaround story with 70% analyst buy ratings and 60% upside potential, though risks include persistent losses, competitive pressures, and technical weakness. The AI cloud partnership with Xiaomi positions the stock for growth, but investors should weigh the fundamental improvements against the current bearish technical setup.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →